Related Experiment Video
Updated: Apr 6, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer
John Syrios1, Georgios Nintos, Vassilis Georgoulias
12nd Department of Medical Oncology, "St. Savvas" Cancer Hospital, 171 Alexandras Av., 11522, Athens, Greece.
Abstract:
Non-small lung cancer (NSCLC) is a lethal malignancy when diagnosed in advanced stage. The evolution of chemotherapy and the development of agents targeting certain molecular pathways involved in tumor progression improved the prognosis. Nintedanib is a new tyrosine kinase inhibitor, which exerts its activity by blocking VEGF, FGF and PDGF receptors and inhibits the angiogenic signaling by preventing receptor dimerization. Several Phase I and II studies proved its safety and efficacy in diverse solid tumors. In patients with advanced NSCLC, the administration of nintedanib may offer an additional chemotherapy benefit in terms of response rate, progression-free survival and overall survival particularly in patients with adenocarcinoma histology, with manageable toxicity. Here, we present an analytical review of literature regarding nintedanib and we focus on its particular importance in NSCLC treatment.
Insights
Nintedanib, a tyrosine kinase inhibitor, shows promise in treating advanced non-small cell lung cancer (NSCLC). This drug improves outcomes like progression-free survival, especially in adenocarcinoma, with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Advanced non-small cell lung cancer (NSCLC) remains a significant challenge.
- Chemotherapy and targeted therapies have improved NSCLC prognosis.
- Nintedanib targets key angiogenic signaling pathways.
Purpose of the Study:
- To review the literature on nintedanib.
- To focus on the importance of nintedanib in NSCLC treatment.
Main Methods:
- Analytical literature review.
- Focus on Phase I and II studies.
- Evaluation of nintedanib's efficacy and safety in NSCLC.
Main Results:
- Nintedanib demonstrated safety and efficacy in solid tumors.
- Nintedanib offers potential chemotherapy benefits in advanced NSCLC.
- Benefits include improved response rate, progression-free survival, and overall survival, particularly in adenocarcinoma histology.
Conclusions:
- Nintedanib is a promising agent for advanced NSCLC treatment.
- It provides additional benefits when combined with chemotherapy.
- Manageable toxicity supports its use in NSCLC patients.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...